Jakob Dynnes Hansen
Director of Finance/CFO chez ASARINA PHARMA AB
Provenance du réseau au premier degré de Jakob Dynnes Hansen
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Food: Specialty/Candy | 16 | |
14
| Public Company | Medical Specialties | 14 |
| Public Company | Pharmaceuticals: Major | 12 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jakob Dynnes Hansen via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Chairman Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Gyros AB
 Gyros AB Medical SpecialtiesHealth Technology Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
Healthcare Businesswomens Association
 Healthcare Businesswomens Association Miscellaneous Commercial ServicesCommercial Services Healthcare Businesswomens Association operates women healthcare associations. The company was founded by Diane Anderson, Peg Dougherty, Millicent Gryczka, Sheila Sinkking and Ruth Smith in 1977 and is headquartered in Fairfield, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NICOX SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Rice University | College/University | Undergraduate Degree | |
Ferring Pharmaceuticals A/S
 Ferring Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals A/S specializes in the development, production and marketing of pharmaceutical products. It offers products in the fields of urology, infertility, obstetrics, gynecology, gastroenterology and maternal health. The company is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | President Chief Executive Officer Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
| The Johns Hopkins University | College/University | Graduate Degree | |
| INSEAD | College/University | Masters Business Admin | |
| University of Uppsala | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director of Finance/CFO | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| US Department of Agriculture | General Government | Corporate Officer/Principal | |
| Royal Institute of Technology | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| University of Basel | College/University | Director/Board Member Undergraduate Degree | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
American Public Health Association
 American Public Health Association Medical/Nursing ServicesHealth Services American Public Health Association provides health care services. | Medical/Nursing Services | Corporate Officer/Principal | |
S*BIO Pte Ltd.
 S*BIO Pte Ltd. Pharmaceuticals: MajorHealth Technology S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Chairman Founder Corporate Officer/Principal Director/Board Member | |
| HANSA BIOPHARMA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
HRA Pharma Development SARL
 HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Pharmaceuticals: Major | Founder Chief Executive Officer | |
| WNTRESEARCH AB | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Laboratoire HRA-Pharma SA
 Laboratoire HRA-Pharma SA Pharmaceuticals: MajorHealth Technology Laboratoire HRA Pharma SA manufactures and distributes pharmaceutical products. Its products include contraceptive pills such as the pill of two days later and EllaOne. The company was founded by Andre Ulmann in 1996 and is headquartered in Paris, France. | Pharmaceuticals: Major | Founder Chairman | |
| NEOS AB | Medical Specialties | Director/Board Member Director/Board Member | |
| BIOM'UP | Medical Specialties | Director/Board Member | |
| K/S Asschenfeldt, Redcote Lane, Leeds | Director/Board Member | ||
Egalet A/S
 Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| Squibb-Novo, Inc. | Chief Tech/Sci/R&D Officer | ||
| ADDLIFE AB | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| Danish Biotech Association | Director/Board Member | ||
| Eirberry Uab | Director/Board Member | ||
| Eirberry SARL | Corporate Officer/Principal | ||
| VWH & Co. AB | Director/Board Member | ||
| Cemag-Care SA | Founder | ||
| Physip SA | Director/Board Member | ||
| Astra Research Centre AB | Chairman Chief Tech/Sci/R&D Officer |
Statistiques
Internationale
| Suède | 15 |
| Danemark | 10 |
| France | 10 |
| Etats-Unis | 7 |
| Suisse | 7 |
Sectorielle
| Health Technology | 25 |
| Consumer Services | 10 |
| Commercial Services | 5 |
| Health Services | 3 |
| Government | 2 |
Opérationnelle
| Director/Board Member | 271 |
| Corporate Officer/Principal | 105 |
| Chairman | 80 |
| Independent Dir/Board Member | 47 |
| Chief Executive Officer | 46 |
Relations les plus connectées
| Insiders | |
|---|---|
| Göran Albert Ando | 44 |
| Ganesh Kishore | 38 |
| Sten Gunnar Otto Skolling | 32 |
| Eva Nilsagård | 30 |
| Birgit Stattin Norinder | 29 |
| Thomas Fulton Wilson McKillop | 28 |
| Ingelise Saunders | 28 |
| Claus Tycho Bræstrup | 27 |
| Mathieu Simon | 22 |
| Jean-Philippe Tripet | 20 |
| Peter Nordkild | 20 |
| Thomas Videbaek | 16 |
| Marianne Kock | 16 |
| Michel Lucien Pettigrew | 16 |
| Erich Schlick | 15 |
- Bourse
- Insiders
- Jakob Dynnes Hansen
- Connexions Sociétés
